

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE
RECEIPT OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND
RETURNING THIS POST CARD.

5 pgs-Recordation-Form Cover Sheet and Assignment for:

08/453,176, 5-30-95; 08/452,242, 5-26-95; 08/452,229, 5-26-95;

08/451,374, 5-26-95; 08/453,183, 5-30-95; 08/448,245, 5-23-95;

~~08/452,183, 5-23-95;~~ 08/052,541, 4-20-93; 07/855,413, 3-19-92;

07/788,423, 11-6-91; 07/774,109, 10-8-91; 07/764,000, 12-22-91;

Titled: Glial Cell Line-Derived Neurotrophic Factor ("GDNF") and

08/446,383, 5-22-95; 08/340,821, 11-15-94

Titled: Method for Using GDNF as a Neuroprotective Agent

RECEIVED
FEB 24 1997

RECEIPT ACCTING DR

DRC/khh

Via First Class Mail

February 18, 1997

Amgen Inc.
1840 DeHavilland Drive
Thousand Oaks, CA 91320-1789

AMGEN

Box Assignment
Assistant Commissioner for Patents
Washington D.C. 20231

RECORDATION FORM COVER SHEET

U.S. Department of Commerce
Patent and Trademark Office

PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party:
Synergen, Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name: Amgen Inc.

Internal

Address:

Street

Address:

1840 DeHavilland Drive

City: Thousand Oaks State: CA Zip: 91320-1789

3. Nature of conveyance:

☒ Assignment

☐ Merger

☐ Security Agreement

☐ Change of Name

☐ Other

Execution Date: December 31, 1994

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application numbers:

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application Nos.: 08/453,176; 08/452,242;
08/452,229; 08/451,374; 08/453,183; 08/448,245;
08/182,183; 08/052,541; 07/855,413; 07/788,423
07/774,109; 07/764,685; 08/446,383; 08/340,821

B. Patent Nos.

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: U.S. Patent Operations/DRC

Internal Address: Dept. 431

Amgen

Street Address: 1840 DeHavilland Drive

City: Thousand Oaks State: CA Zip: 91320-1789

6. Total number of applications and patents involved: 14

7. Total fee (37 CFR 3.41).....\$ 560.00

☐ Enclosed

☒ Authorized to be charged to deposit account.

8. Deposit account number: 01-0519

☒ The Commissioner is hereby authorized to charge any additional filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

Daniel R. Curry

Name of Person Signing

Signature

February 18, 1997

Date

Total number of pages including cover sheet, attachments, and document: 5

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Box Assignment, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

2/18/97

Date

Freddie Craft

Signature

ASSIGNMENT OF PATENT RIGHTS

This Assignment of Patent Rights (hereafter, "Assignment") is made as of December 31, 1994 by Synergen, Inc., a Delaware corporation, having its principal place of business at c/o Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, California 91320 (hereafter, "Synergen") to Amgen Inc., a Delaware corporation, having its principal place of business at Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, California 91320 (hereafter, "Amgen").

RECITALS

1. Synergen is the exclusive owner of all right, title to, and interest in patent applications relating to Glial Cell Line-Derived Neurotrophic Factor pending in the United States Patent and Trademark Office and all foreign counterparts (referred to jointly hereafter as the "Patent Applications"), including those set forth on attached Exhibit A.

2. Synergen has agreed that the Patent Applications are unencumbered and that Synergen has full right and lawful authority to assign and convey the same in the manner set forth herein.

3. Synergen has agreed to transfer and assign all of its right, title to, and interest in the Patent Applications to Amgen.

AGREEMENT

In consideration of the sum of one dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, Synergen hereby sells, transfers and assigns to Amgen, its successors and assigns the entire right, title and interest in, to and under the Patent Applications, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all Letters Patent of the United States and Patents and of all other countries which may be granted for such inventions, or any of them including divisional, continuation, continuation-in-part, renewal or substitute applications based on the above-identified Patent Applications, any reissue or re-examination of patents and Letters Patent, all such inventions and all rights in such

Patents and Letters Patent to be held and enjoyed by Amgen for its own use and enjoyment to the full end of the term or terms for which such Patents and Letters Patent may be granted.

Synergen further transfers and assigns all claims for damages and/or injunctive relief by reason of past infringement of the Patent Applications and all foreign counterparts thereto, with the right to sue for and collect the same for Amgen's own account and use.

Synergen further transfers and assigns to Amgen the full exclusive benefits of, and all rights, privileges and advantages appertaining to the Patent Applications.

IN WITNESS WHEREOF, the duly authorized representative of Synergen has executed this Assignment as of the date first written above.

Synergen, Inc.

By: 

Name: Robert Attiyeh

Title: Senior Vice President,
Finance & Corporate Development

CALIFORNIA ALL-PURPOS. ACKNOWLEDGMENT

State of California
 County of Ventura
 On April 23, 1996 before me, C. Michi Hasegawa
Date Name and Title of Officer (e.g., "Jane Doe, Notary Public")
D.N.A. & Att. 101

APOSTILLE


(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America
This public document
2. has been signed by C. MICHI HASEGAWA
3. acting in the capacity of Notary Public, State of California
4. bears the seal/stamp of C. MICHI HASEGAWA Notary Public,
State of California

CERTIFIED

5. at Sacramento, California
6. the 2ND DAY OF MAY 1996
- by Deputy Secretary of State, State of California
8. No NP02619
9. Seal/Stamp
10. Signature: [Signature]

SOS/NP 28 12/95



- ☐ Individual
☒ Corporate Officer
 Title(s): SVP - Finance & Corp Dev
☐ Partner — ☐ Limited ☐ General
☐ Attorney-in-Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

RIGHT THUMBPRINT
OF SIGNER
Top of thumb here

Signer Is Representing:

- ☐ Individual
☐ Corporate Officer
 Title(s): _____
☐ Partner — ☐ Limited ☐ General
☐ Attorney-in-Fact
☐ Trustee
☐ Guardian or Conservator
☐ Other: _____

RIGHT THUMBPRINT
OF SIGNER
Top of thumb here

Signer Is Representing:

EXHIBIT A

U.S. Patent Application

<u>Serial No:</u>	<u>Date Filed</u>	<u>Title</u>
08/453,176	05-30-95	Glial Cell Line-Derived Neurotrophic Factor ("GDNF")
08/452,242	05-26-95	Same
08/452,229	05-26-95	Same
08/451,374	05-26-95	Same
08/453,183	05-30-95	Same
08/448,245	05-23-95	Same
08/182,183	05-23-95	Same
08/052,541	04-20-93	Same
07/855,413	03-19-92	Same
07/788,423	11-06-91	Same
07/774,109	10-08-91	Same
07/764,685	09-20-91	Same
08/446,383	05-22-95	Method for Using GDNF as a Neuroprotective Agent
08/340,821	11-15-94	Same

Foreign Patent Application

<u>Serial No/Country:</u>	<u>Date Filed</u>	<u>Title</u>
26811/92/AU	09-17-92	Glial Derived Neurotrophic Factor
1053/BS	09-17-92	Same
2119463/CA	09-17-92	Same
92921022.7/EP	09-17-92	Same
941285/FI	09-17-92	Same
P9400717/HU	09-17-92	Same
103223/IE	09-17-92	Same
103223/IL	09-17-92	Same
506234/93/JP	09-17-92	Same
700860/94/KR	09-17-92	Same
925293/MX	09-17-92	Same
9409222/NO	09-17-92	Same
244392/NZ	09-17-92	Same
44956/PH	09-18-92	Same
100879/PT	09-17-92	Same
81108487/TW	09-17-92	Same
US92/07888/PCT	09-17-92	Same
92/7159/ZA	09-17-92	Same
115996/IL	11/12/95	Methods of Using GDNF as a Neuroprotective Agent
IB95/01004/PCT	11/13/95	Same
95/9714/ZA	11/15/95	Same